Scarica l'app Stockscreener
5.87
3.35%
0.19
Dopo l'orario di chiusura:
5.89
0.02
+0.34%
Precedente Chiudi:
$5.68
Aprire:
$5.59
Volume 24 ore:
2.39M
Relative Volume:
2.19
Capitalizzazione di mercato:
$300.97M
Reddito:
$676.80M
Utile/perdita netta:
$-8.60M
Rapporto P/E:
-20.75
EPS:
-0.2829
Flusso di cassa netto:
$135.40M
1 W Prestazione:
-5.78%
1M Prestazione:
+31.32%
6M Prestazione:
-30.04%
1 anno Prestazione:
-26.35%
Intervallo 1D:
$5.50
$5.99
Intervallo di 1 settimana:
$5.50
$6.30
Portata 52W:
$4.36
$14.06
Emergent Biosolutions Inc Stock (EBS) Company Profile
Nome
Emergent Biosolutions Inc
Settore
Telefono
240-631-3200
Indirizzo
300 PROFESSIONAL DR, GAITHERSBURG, MD
Compare EBS vs TAK, TEVA, HLN, ZTS, UTHR
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
EBS
Emergent Biosolutions Inc
|
5.87 | 291.23M | 676.80M | -8.60M | 135.40M | -0.2829 |
TAK
Takeda Pharmaceutical Co Adr
|
18.11 | 58.15B | 29.91B | 1.30B | 3.49B | 0.4056 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
36.35 | 42.94B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.22 | 40.59B | 14.54B | 2.22B | 2.58B | 0.4871 |
ZTS
Zoetis Inc
|
72.86 | 30.29B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
503.86 | 21.74B | 3.17B | 1.29B | 1.01B | 27.09 |
Emergent Biosolutions Inc Stock (EBS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2024-03-07 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-08-29 | Downgrade | The Benchmark Company | Buy → Hold |
| 2023-04-10 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2023-03-17 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-11-10 | Downgrade | The Benchmark Company | Buy → Hold |
| 2022-04-29 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2022-01-20 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2021-11-08 | Downgrade | The Benchmark Company | Buy → Hold |
| 2021-05-05 | Downgrade | Argus | Buy → Hold |
| 2021-04-07 | Iniziato | The Benchmark Company | Buy |
| 2021-02-24 | Aggiornamento | Chardan Capital Markets | Neutral → Buy |
| 2021-02-19 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| 2021-01-08 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-07-31 | Reiterato | Chardan Capital Markets | Buy |
| 2019-09-12 | Iniziato | Guggenheim | Buy |
| 2019-09-04 | Aggiornamento | Wells Fargo | Market Perform → Outperform |
| 2018-11-02 | Aggiornamento | Goldman | Neutral → Buy |
| 2018-08-03 | Reiterato | Chardan Capital Markets | Buy |
| 2018-06-13 | Iniziato | Argus | Buy |
| 2018-04-25 | Downgrade | Wells Fargo | Outperform → Market Perform |
| 2018-01-24 | Iniziato | Goldman | Neutral |
| 2018-01-16 | Reiterato | Chardan Capital Markets | Buy |
| 2016-06-28 | Reiterato | Singular Research | Buy |
| 2016-04-15 | Iniziato | Chardan Capital Markets | Buy |
| 2016-03-28 | Iniziato | Singular Research | Buy |
| 2016-02-19 | Iniziato | Wells Fargo | Outperform |
| 2014-05-15 | Iniziato | Summer Street Research | Buy |
| 2011-05-31 | Reiterato | WBB Securities | Strong Buy |
| 2011-01-10 | Reiterato | Wedbush | Outperform |
| 2010-11-05 | Reiterato | Wedbush | Outperform |
| 2010-08-18 | Aggiornamento | WBB Securities | Buy → Strong Buy |
| 2010-08-06 | Reiterato | Caris & Company | Buy |
Mostra tutto
Emergent Biosolutions Inc Borsa (EBS) Ultime notizie
Intravenous Immunoglobulin Market Size Worth USD 30.83 Billion by 2035, Growing at 7.49% CAGR – SNS Insider - GlobeNewswire Inc.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Emergent BioSolutions Inc. - GlobeNewswire Inc.
Emergent Biosolutions Inc (EBS) Fundamental & Financial Data - Stocktwits
Emergent BioSolutions: Tough 2026 Outlook Warrant Rating Downgrade (NYSE:EBS) - Seeking Alpha
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutions Inc. (EBS) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Emergent Biosolutions Stock Price Forecast. Should You Buy EBS? - StockInvest.us
Bronstein, Gewirtz & Grossman, LLC Encourages Emergent BioSolutio - The National Law Review
Bronstein, Gewirtz & Grossman, LLC Is Investigating Emergent BioS - The National Law Review
Emergent BioSolutions repurchases $75 million in senior notes By Investing.com - Investing.com Australia
Emergent BioSolutions Repurchases $75 Million of Debt at Discount - citybiz
Emergent BioSolutions faces securities fraud pr... - Pluang
Gaithersburg's Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS - BioBuzz
Emergent BioSolutions repurchases $75 million in senior notes - Investing.com
Emergent BioSolutions Repurchases $75 Million of Senior Unsecured Notes, Reducing Debt to $364.7 Million - quiverquant.com
Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes - marketscreener.com
A $68 million cash outlay retires $75 million in Emergent bond debt - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Shareholders to Reach Out - ACCESS Newswire
Emergent BioSolutions | 8-K: Current report - Moomoo
Emergent BioSolutions receives $24 million BARDA contract - grafa.com
2026-09-01 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Shareholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. Receives Contract Modification Valued At Approximately USD 24 Million From The Biomedical Advanced Research And Development Authority To Supply CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) - marketscreener.com
Emergent BioSolutions receives $24M anthrax vaccine contract By Investing.com - Investing.com Australia
EBS Looks 11.9% Overvalued on GF Value™ Amid Challenging Growth Outlook - GuruFocus
Emergent BioSolutions receives $24M anthrax vaccine contract - Investing.com
Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) - The Manila Times
Emergent BioSolutions Awarded $24M CYFENDUS Contract | EBS Stock News - Stock Titan
Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray - Bioscience Association Manitoba
EBS Looks 8.4% Overvalued on GF Value™ Amid Challenging Growth O - GuruFocus
Emergent BioSolutions wins Canada contract for overdose spray By Investing.com - Investing.com Nigeria
Emergent BioSolutions wins Canada contract for overdose spray - Investing.com Canada
Emergent BioSolutions Awarded Canadian Government Standing Offer for NARCAN Nasal Spray - Quiver Quantitative
Canadian public agencies can buy NARCAN for three years; the spray lasts four - Stock Titan
Emergent BioSolutions Expands Ready to Rescue Campaign on U.S. Campuses and in Canada for International Overdose Awareness Day - quiverquant.com
2026-08-30 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Investors to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
Emergent BioSolutions Inc. (EBS) Options Chain - finance.yahoo.com
Emergent Biosolutions Inc (EBS) Shareholding Pattern – Promoters, FIIs & DIIs - valueresearchonline.com
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Emergent BioSolutions Inc. (EBS) And Encourages Stockholders to Reach Out - ACCESS Newswire
EBS Reinstated by JP Morgan -- Current Rating Underweight - GuruFocus
2026-08-21 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Emergent BioSolutions Inc. (EBS) and Encourages Stockholders to Learn More About the Investigation | NYSE:EBS | Press Release - Stockhouse
JPMorgan Chase & Co. Begins Coverage on Emergent Biosolutions (NYSE:EBS) - MarketBeat
EBS Looks 11.9% Undervalued on GF Value™ Despite Underweight Rat - GuruFocus
The Friday Brief for August 21, 2026: Partners Sharpen Their Focus - Contract Pharma
Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today? - Stocktwits
Emergent BioSolutions Inc at Goldman Sachs Healthcare Conference Transcript - GuruFocus
Emergent (EBS) Price: Gains 4.94% to Reach $4.89 at the Close; Immediate View: the Near-Term Reference Band Stretches From $4.65 to $5.13 on the DayPrice Target - vinanet.vn
Emergent BioSolutions Balances Q2 Beat With Tough Outlook - The Globe and Mail
S&P downgrades Emergent BioSolutions outlook on competition By Investing.com - Investing.com Nigeria
S&P downgrades Emergent BioSolutions outlook on competition - Investing.com
Securities Fraud Investigation Into Emergent BioSolutions Inc. (EBS) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz - Business Wire
Emergent BioSolutions (EBS) Holds Above Support as Shares Slip 0.33%Volume Oscillator - vinanet.vn
Emergent BioSolutions Inc (EBS) (Q2 2026) Earnings Call Highligh - GuruFocus
Emergent Biosolutions Inc Azioni (EBS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.56%
1.43%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):